Compile Data Set for Download or QSAR
maximum 50k data
Found 280 Enz. Inhib. hit(s) with Target = 'Serine/threonine-protein kinase SIK2'
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647342(4-(7-(1- cyclopropyl- 1H-pyrazol-4- yl)imidazo[1,2...)
Affinity DataIC50:  0.101nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM50601538(CHEMBL5090394)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of GST-tagged human SIK2 autophosphorylation measured after 30 mins in presence of [gamma33P]ATP by Western blot analysisMore data for this Ligand-Target Pair
In DepthDetails PubMed
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM2579((2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-2...)
Affinity DataIC50:  0.345nMAssay Description:Inhibition of human SIK2 using AMARAASAAALARRR as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM2579((2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-2...)
Affinity DataIC50:  0.370nMAssay Description:Inhibition of human SIK2 using AMARAASAAALARRR as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647344(US20240025892, Example 51)
Affinity DataIC50:  0.412nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647338(US20240025892, Example 45)
Affinity DataIC50:  0.579nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647340(4-(7-(1-ethyl-1H- pyrazol-4- yl)imidazo[1,2- a]pyr...)
Affinity DataIC50:  0.855nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647298(2-(5-((3-methyloxetan- 3-yl)methoxy)-1H- benzo[d]i...)
Affinity DataIC50:  0.979nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM50601534(CHEMBL4539742)
Affinity DataIC50:  1nMAssay Description:Inhibition of SIK2 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647310(US20240025892, Example 17)
Affinity DataIC50:  1.04nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647345(US20240025892, Example 52)
Affinity DataIC50:  1.11nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647348(US20240025892, Example 55)
Affinity DataIC50:  1.48nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647353(2-cyclopropyl-5- (2,6-dimethoxy- 4-(7-(1-methyl- 1...)
Affinity DataIC50:  1.49nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647346(2-(4-(6-(1- cyclopropyl-1H- pyrazol-4- yl)pyrazolo...)
Affinity DataIC50:  1.77nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647308(US20240025892, Example 15)
Affinity DataIC50:  1.91nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647303(US20240025892, Example 10)
Affinity DataIC50:  2.11nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647347(4-(6-(1-cyclopropyl- 1H-pyrazol-4- yl)pyrazolo[1,5...)
Affinity DataIC50:  2.24nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647343(4-(7-(1- (oxetan-3-yl)- 1H-pyrazol-4- yl)imidazo[1...)
Affinity DataIC50:  2.34nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647337(US20240025892, Example 44)
Affinity DataIC50:  2.34nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647354(US20240025892, Example 61)
Affinity DataIC50:  3.07nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647309(US20240025892, Example 16)
Affinity DataIC50:  3.39nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647356(US20240025892, Example 63)
Affinity DataIC50:  3.40nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM192712(HG-9-91-01 (1))
Affinity DataIC50:  3.5nMpH: 8.0Assay Description:IC50‘s for HG-9-91-01 derivatives were measured by Caliper-based mobility shift assay (PerkinElmer). For these experiments, full length His6-MBP...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM13216(BMS-354825 | CHEMBL1421 | DASATINIB | N-(2-Chloro-...)
Affinity DataIC50:  3.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM632979(US20230348453, Compound D7)
Affinity DataIC50:  3.5nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM50152595(CHEMBL3780091)
Affinity DataIC50:  4nMAssay Description:Inhibition of SNF1LK2 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647334(US20240025892, Example 41)
Affinity DataIC50:  4.11nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647306(US20240025892, Example 13)
Affinity DataIC50:  4.19nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM50148921(CHEMBL3770443)
Affinity DataIC50:  4.40nMAssay Description:Inhibition of GST-tagged human SIK2 autophosphorylation measured after 30 mins in presence of [gamma33P]ATP by Western blot analysisMore data for this Ligand-Target Pair
In DepthDetails PubMed
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647305(US20240025892, Example 12)
Affinity DataIC50:  4.90nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647315(N-((1H- benzo[d]imidazol-2- yl)methyl)-3-(4- cyano...)
Affinity DataIC50:  5.58nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647299(2-(5-((3-methyloxetan- 3-yl)methoxy)-1H- benzo[d]i...)
Affinity DataIC50:  5.75nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM50055496(CHEMBL3326006)
Affinity DataIC50:  5.80nMAssay Description:Inhibition of N-terminal GST-tagged full length human QIK (1 to 926 end residues) expressed in baculovirus expression system using fluorecence-labele...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM50055496(CHEMBL3326006)
Affinity DataIC50:  5.80nMAssay Description:Inhibition of QIK (unknown origin) by Off-chip Mobility Shift AssayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647336(US20240025892, Example 43)
Affinity DataIC50:  5.89nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM192714(US11725011, Compound YKL-05-95 | YKL-05-095 (3))
Affinity DataIC50:  6nMpH: 8.0Assay Description:IC50‘s for HG-9-91-01 derivatives were measured by Caliper-based mobility shift assay (PerkinElmer). For these experiments, full length His6-MBP...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM192714(US11725011, Compound YKL-05-95 | YKL-05-095 (3))
Affinity DataIC50:  6nMAssay Description:IC50's for selected compounds in Table 5 below were measured by Caliper-based mobility shift assay (PerkinElmer). For these experiments, full len...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647328(US20240025892, Example 35)
Affinity DataIC50:  7.55nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647341(US20240025892, Example 48)
Affinity DataIC50:  7.65nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647300(1-(2-(5-((3- methyloxetan-3- yl)methoxy)-1H- benzo...)
Affinity DataIC50:  8.35nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647350(2-ethyl-5-(2- methoxy-4-(7- (1-methyl-1H- pyrazol-...)
Affinity DataIC50:  8.76nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647357(US20240025892, Example 64)
Affinity DataIC50:  8.80nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM50148921(CHEMBL3770443)
Affinity DataIC50:  9nMAssay Description:Inhibition of human SIK2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647318(N-((3H-imidazo[4,5- c]pyridin-2- yl)methyl)-3-(4- ...)
Affinity DataIC50:  9.74nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM647333(2,6-dimethoxy-4-(7-((3- methyloxetan-3- yl)methoxy...)
Affinity DataIC50:  9.87nMAssay Description:Assays were performed in base reaction buffer (20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM DTT, 1...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM632971(N-(2-chloro-4-(fluoromethyl)thiophen- 3-yl)-2-((2-...)
Affinity DataIC50: <10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM632975(N-(2-chloro-4- (difluoromethyl)thiophen-3-yl)-2-((...)
Affinity DataIC50: <10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM632968(N-(2-chloro-4-(fluoromethyl)thiophen- 3-yl)-2-((6-...)
Affinity DataIC50: <10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM632967(N-(4-chloro-2-fluorothiophen-3-yl)-2- ((6-(4-(2-hy...)
Affinity DataIC50: <10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSerine/threonine-protein kinase SIK2(Homo sapiens (Human))
The General Hospital

US Patent
LigandPNGBDBM632973(N-(2-chloro-4-(fluoromethyl)thiophen- 3-yl)-2-((2-...)
Affinity DataIC50: <10nMAssay Description:The IC50 for the inhibition of ABL1 by dasatinib, by C7 and by B3 is approximately 1.5 nM, 5.1 nM and 1.6 nM, and of SRC is 1.5 nM, 1.5 nM and 1.5 nM...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 280 total ) | Next | Last >>
Jump to: